I

Promising results on intravitreal injections of this treatment on ARMD have been demonstrated in phase II trials; phase II trials on diabetic macular edema are starting. A major limitation of both treatments is the need for repeated intraocular injection, with its risks including endophtalmitis and retinal detachment… ................
................